

RedShiftBio Expands Team to Support Launch of FlagShip AQS3™pro System for Protein Characterization

Burlington, MA 14 March 2018. Following the introduction of the AQS3™pro, a new protein characterization platform that allows users to ‘See Change™’, in the secondary structure of proteins, RedShiftBio has announced that it is expanding its team with key hires. The growth will enable the company to fulfil high demand for the new instrument.

John Linnan, a sales and marketing executive with a strong background in the life sciences, joins the company as North American sales manager. John’s career has spanned start-ups to industry leaders. As Global VP of Sales and Marketing, he helped transition Agencourt BioScience into a wholly-owned subsidiary of Beckman Coulter. He also developed and executed the commercialization strategy for QIAGEN Custom Solutions (formally Enzymatics) for enzyme manufacturing and OEM solutions targeting biotech drug & diagnostics development. This experience makes John the perfect appointment to help build our commercial channels for our new technology platform.

The AQS3pro is designed for the development, formulation and manufacture of biotherapeutics. Enabling five key measurements—aggregation, quantitation, stability, similarity, structure—the AQS3pro ramps up the sensitivity, dynamic range and accuracy of IR spectroscopy over the concentration range of 0.1 to 200mg/mL. It features a powerful, integrated bioanalytics software that delivers automated, high sensitivity spectroscopic analysis.

If you would like to find out more about the AQS3pro then visit <https://redshiftbio.com/mms>.

- ENDS -

High resolution image attached, Image Caption: John Linnan joins RedShiftBio as North American sales manager



About

RedShiftBio is a provider of innovative analytical instrumentation for the research, development and manufacture of protein therapeutic drugs. The company has developed the AQS3pro featuring a powerful new analytical technique, Microfluidic Modulation Spectroscopy, or MMS, that enables direct probing of the biophysical structure of proteins. The patented MMS technology provides the comprehensive structural information across five key measurements, in a single automated analysis, replacing the requirement to run samples on multiple instruments. For further information, please visit www.redshiftbio.com/collaboration, or email info@redshiftbio.com

To find out more about RedShiftBio:

Please visit www.redshiftbio.com/mms, or email info@redshiftbio.com

For media enquiries in Europe

Contact:

Claire England

claire@covalentbonds.com

+44 (0) 7808 020554

For media enquiries in the USA

Contact:

Laura Browne

laura@covalentbonds.com

+1 978 893 9618